Bristol-Myers Squibb CEO Giovanni Caforio told CNBC on Friday the company is"one step closer to creating that great company" after shareholders greenlit a $74 billion takeover of Celgene.
"When the two companies come together, we'll have two growing businesses," Caforio said in an interview with "Mad Money's" Jim Cramer."We're going to be able to launch six new medicines, potentially, in the next two years. It's going to be a great company, [will] create value for shareholders, [and will be] very good for patients."
Celgene is also a leader, he added, in treatments for multiple myeloma, a cancer that attacks the plasma cells that create antibodies to fight infections.
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Here’s one way to tell if a company is overpaying its CEOU.S. companies that use non-standard numbers to calculate executive compensation are overpaying their top managers, according to a new research report. Step 1: Is your CEO a WASP male? Step 2: If yes, your CEO is overpaid. If no see Step 3. Step 3: Your CEO is not overpaid. thanks for info marketwatch
Fonte: MarketWatch - 🏆 3. / 97 Leggi di più »
Exclusive: Trump eyeing stepped-up Venezuela sanctions for foreign companies - BoltonWATCH: Trump is eyeing 'secondary sanctions' on Venezuela that would hit companies from other countries who do business with Maduro's government, national security adviser Bolton said Yup. He still looks like a loony OH NOOO! New sanctions again!!! GAME OVER!!!
Fonte: Reuters - 🏆 2. / 97 Leggi di più »
Disney CEO Iger gives three reasons why the company's streaming service will be a successDisney Chairman and CEO Bob Iger explained that he believes customers will flock to Disney+ thanks to a combination of unique factors. RobertIger Stocks sky high
Fonte: CNBC - 🏆 12. / 72 Leggi di più »